Video

Dr. Mathew Hall on the Impact of PSA Screening Recommendations

Author(s):

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

In 2012 The US Preventive Services Task Force (USPSTF) finalized a recommendation that stated that PSA screening was unnecessary in all men. To determine if this recommendation is correct, Hall and his team measured PSA in National Comprehensive Cancer Network (NCCN) risk groups of men diagnosed with prostate cancer.

Their study looked at data from 2005 to 2013 on age, race, PSA, Gleason score, t-stage, and presence or absence of metastatic disease. The data analyzed came from 87,500 men from cancer centers throughout the country.

They found that prior to 2011 there was a slow but significant decline in the number of men with prostate cancer diagnosed with a PSA score greater than 10. After 2011, when the USPSTF recommendation was first introduced, this percentage increased at 3% per year.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD